No Detail Found!

Expression and Signi cance of PKM1 in Acute Myeloid Leukaemia

Author(s)
Shanhu Zhu Department of Haematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Xiaolin Liang Department of Haematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Xiaoke Huang Department of Haematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China; Key Laboratory of Haematology, Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
Yibin Yao Department of Haematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China; Key Laboratory of Haematology, Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
Zhongyuan Tang Department of Haematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China; Key Laboratory of Haematology, Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
Zhenfang Liu Department of Haematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China; Key Laboratory of Haematology, Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
Abstract
Objective: To investigate the expression level of pyruvate kinase M1 (PKM1) in patients with acute myeloid leukaemia (AML) as well as its clinical signi cance. Study Design: A case-control study. Place and Duration of the Study:Department of Haematology, The First A liated Hospital of Guangxi Medical University, Nanning, Guangxi, China, from January 2013 to 2023. Methodology: The expression levels of PKM1 and pyruvate kinase m2 (PKM2) in the bone marrow of 65 AML patients (excluding M3) and 31 healthy volunteers were determined using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), a method that measures uorescence in real-time. The associations between PKM1, PKM2 expressions, clinical parameters, and the survival and prognosis of AML patients were analysed. Results: AML patients showed higher PKM1 expression compared to controls. The area under the curve (AUC) of thereceiver operating characteristics (ROC) was 0.65 (p = 0.017). PKM1 expression was correlated with peripheral blood leukocyte count (r = -0.276, p = 0.026), CCAAT enhancer-binding protein alpha CEBPA mutation (r = -0.306, p = 0.014), and chemotherapy-induced response (r = -0.292, p = 0.018). Patients with high PKM1 expression had a lower remission rate (p = 0.019) and long-term survival rate (p = 0.034) than those with low PKM1 expression. Patients with AML showed a rise in PKM2 levels; however, the variation was not statistically signi cant (p >0.05). Conclusion: PKM1 expression is upregulated in AML and patients with high PKM1 expression have a lower survival rate.
Publication Details
Page(s) 811-816
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 7, Year: 2024

Request the full text from PASTIC

Keywords
Acute myeloid leukaemia, PKM1, Clinical prognosis
0

Citations

0

Downloads

183

Views